Document Detail

Transitional changes in T-cell responses to Mycobacterium tuberculosis-specific antigens during treatment.
MedLine Citation:
PMID:  18848730     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Currently, there is no available test for monitoring the clinical effect of active tuberculosis (TB) disease treatment. Therefore, we studied the usefulness of two commercial IFN-gamma assays (QuantiFERON TB-2G (QFT-2G) and T-SPOT.TB tests) for monitoring clinical efficacy. METHODS: The subjects were 40 patients with active TB disease. These two commercial IFN-gamma assays were carried out every three months during active TB disease treatment. RESULTS: While the positive response rate of QFT-2G test significantly decreased from 83% at treatment initiation to 58% at treatment completion, that of T-SPOT.TB decreased from 90% at treatment initiation to 63% at treatment completion. Although there was a significant decrease in patients with TB infection showing positive responses for ESAT-6 only or CFP-10 only antigens on both IFN-gamma assays, there was no significant decrease in patients showing positive responses for both ESAT-6 and CFP-10 antigens on both IFN-gamma assays. On both QFT-2G test and T-SPOT.TB test, the mean values of the IFN-gamma levels in the pre- and post-treatment responses showed significantly decreased responses to CFP-10. On the other hand, smear conversion results of clinical specimens were obtained in all patients at treatment completion. CONCLUSIONS: Antituberculous treatment induced a significant decrease in T-cell responses to separate ESAT-6 and CFP-10 antigens as measured by both IFN-gamma assays. Although IFN-gamma assays might be later than smear conversion results of clinical specimens, the quantitative responses especially to CFP-10 may be one of the useful monitoring markers of clinical efficacy for active TB disease treatment.
Yoshihiro Kobashi; Keiji Mouri; Shinichi Yagi; Yasushi Obase; Naoyuki Miyashita; Mikio Oka
Publication Detail:
Type:  Evaluation Studies; Journal Article     Date:  2008-10-10
Journal Detail:
Title:  The Journal of infection     Volume:  58     ISSN:  1532-2742     ISO Abbreviation:  J. Infect.     Publication Date:  2009 Mar 
Date Detail:
Created Date:  2009-03-09     Completed Date:  2009-04-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7908424     Medline TA:  J Infect     Country:  England    
Other Details:
Languages:  eng     Pagination:  197-204     Citation Subset:  IM    
Division of Respiratory Diseases, Department of Medicine, Kawasaki Medical School, Kurashiki, Okayama, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antigens, Bacterial / immunology
Antitubercular Agents / immunology*,  therapeutic use*
Bacterial Proteins / immunology
Drug Monitoring / methods*
Interferon-gamma / secretion
Middle Aged
Mycobacterium tuberculosis / immunology
Sputum / microbiology
T-Lymphocytes / immunology*
Tuberculosis / drug therapy*,  immunology*
Reg. No./Substance:
0/Antigens, Bacterial; 0/Antitubercular Agents; 0/Bacterial Proteins; 0/CFP-10 protein, Mycobacterium tuberculosis; 0/ESAT-6 protein, Mycobacterium tuberculosis; 82115-62-6/Interferon-gamma

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Evaluation of ChloraPrep (2% chlorhexidine gluconate in 70% isopropyl alcohol) for skin antisepsis i...
Next Document:  Reliability, validity and ability to detect change of the Personal and Social Performance scale in p...